Search Results

Ma focused on investments in digitization of industry, resource efficiency, mobility, renewable energy the focus on neurodegeneration and neurodevelopmental diseases, Anavex is tackling one of the biggest medical (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated projected in any of such statements due to various factors, including the risks set forth in the Company’s most

Simuni earned her Bachelor of Science and medical degrees from Leningrad Medical School, Russia. Research Awards, Northwestern Department of Neurology Teacher of the Year Award, and the Northwestern Medical Parkinson’s Disease Research, Education and Clinical Center (PADRECC) at the Philadelphia Veterans Affairs Medical projected in any of such statements due to various factors, including the risks set forth in the Company’s most Dobson Media Group (203) 258-0159 dennisdobsonjr@dobsonmediagroup.com

Parkinson’s Research and its international partners has committed to invest into Anavex up to 50% of the costs Further information is available at https://shakeitup.org.au/. It is the second most common neurological disorder and approximately one million people in the United (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Investors & Media: Email

A live webcast is available at: https://www.webcaster4.com/Webcast/Page/2495/37416. C. A live webcast is available to clients of the firm at https://hcwevents.com/. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Investors & Media: Email

(Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics Barwicki Investor Relations Tel: 516-662-9461 Email: andrew@barwicki.com [1] https://www.anavex.com /post/anavex-life-sciences-announces-anavex-2-73-significantly-prevented-aβ-abeta-induced-deficits Neuro-degenerative diseases , 16 (1-2), 95–110. https://doi.org/10.1159/000440864 [5] https://www.anavex.com /post/anavex-life-sciences-reports-positive-results-from-phase-1-clinical-trial-of-anavex-3-71

Given the potential therapeutic benefit of cannabis as well as the increased use of medical marijuana (OTCQX: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel drug projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Shareholder & Media

There is a significant unmet medical need in the development of Parkinson’s disease therapies that could (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Investors & Media

Fragile X syndrome (FXS) is the most common form of inherited intellectual disability and the most frequent intellectual disability and the most frequent single gene cause of autism, affecting approximately 1 Autism spectrum disorder is a behavioral diagnosis while Fragile X syndrome is a medical/genetic diagnosis (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics Barwicki Investor Relations Tel: 516-662-9461 Email: andrew@barwicki.com [1]https://fragilex.org/understanding-fragile-x

Anavex is utilizing innovative strategies in trial design in order to effectively and efficiently translate For most affected children, their early development appears normal but then slows down or suddenly halts Walter E Kaufmann, MD, Chief Medical Officer of Anavex commented, “ANAVEX®2-73 highlights our commitment (RSAA) is a not-for-profit organisation which is managed by a Committee of volunteers, most of whom are Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Investors & Media:

The Anavex presentation will be webcast live at: http://www.veracast.com/webcasts/bio/ceoinvestor2012 About Alzheimer’s Disease While Alzheimer’s Disease is most common in people over the age of 65, it can Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1

dihydrogen phosphate salt of ANAVEX®2-73 (blarcamesine), freebase, transdermal patches and enteric coated forms which differ in their physical properties’. [ 1]  These property differences may result in direct medical (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics projected in any of such statements due to various factors, including the risks set forth in the Company’s most

RSBQ-CGI-I correlations),” said Walter E Kaufmann, MD, Principal Investigator of the study and Chief Medical Principal Investigator of the study and Chief Medical Officer of Anavex, Walter E Kaufmann, MD presented (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Investors & Media: